As of 2024-12-11, the Relative Valuation of Cogent Biosciences Inc (COGT) is (60.98) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.50 USD, the upside of Cogent Biosciences Inc based on Relative Valuation is -741.9%.
The range of the Relative Valuation is (62.21) - (69.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.4x - 44.7x | 35.0x |
| Forward P/E multiples | 20.3x - 31.5x | 20.6x |
| Fair Price | (62.21) - (69.05) | (60.98) |
| Upside | -754.8% - -826.9% | -741.9% |
| Date | P/E |
| 2024-12-09 | -4.41 |
| 2024-12-06 | -4.05 |
| 2024-12-05 | -4.10 |
| 2024-12-04 | -4.20 |
| 2024-12-03 | -4.19 |
| 2024-12-02 | -4.32 |
| 2024-11-29 | -4.34 |
| 2024-11-27 | -4.37 |
| 2024-11-26 | -4.39 |
| 2024-11-25 | -4.19 |
| 2024-11-22 | -4.16 |
| 2024-11-21 | -4.09 |
| 2024-11-20 | -4.14 |
| 2024-11-19 | -4.13 |
| 2024-11-18 | -4.10 |
| 2024-11-15 | -4.06 |
| 2024-11-14 | -4.40 |
| 2024-11-13 | -4.74 |
| 2024-11-12 | -4.73 |
| 2024-11-11 | -4.74 |
| 2024-11-08 | -4.65 |
| 2024-11-07 | -4.58 |
| 2024-11-06 | -4.78 |
| 2024-11-05 | -4.55 |
| 2024-11-04 | -5.41 |
| 2024-11-01 | -5.34 |
| 2024-10-31 | -5.24 |
| 2024-10-30 | -5.48 |
| 2024-10-29 | -5.47 |
| 2024-10-28 | -5.42 |
| 2024-10-25 | -5.46 |
| 2024-10-24 | -5.48 |
| 2024-10-23 | -5.61 |
| 2024-10-22 | -5.58 |
| 2024-10-21 | -5.41 |
| 2024-10-18 | -5.43 |
| 2024-10-17 | -5.31 |
| 2024-10-16 | -5.17 |
| 2024-10-15 | -5.32 |
| 2024-10-14 | -5.16 |
| 2024-10-11 | -5.13 |
| 2024-10-10 | -5.06 |
| 2024-10-09 | -4.92 |
| 2024-10-08 | -4.95 |
| 2024-10-07 | -4.90 |
| 2024-10-04 | -5.06 |
| 2024-10-03 | -4.81 |
| 2024-10-02 | -4.89 |
| 2024-10-01 | -4.90 |
| 2024-09-30 | -4.92 |